CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionReturn on equity is -214.6%, lower than 95% of its Biotechnology peers (median -23.8%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
601.96MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.2420xvs all stocks
52-Week Change
172.38%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
601.96MUSDvs all stocks (USD)
Enterprise Value
580.27MUSDvs all stocks (USD)
Forward P/E
-19.26xvs Biotechnology peers
Price to Book (MRQ)
54.38xvs Biotechnology peers
Enterprise to EBITDA
-21.04xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-73.07%vs Biotechnology peers
Return on Equity (TTM)
-214.58%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Oct 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-30.27MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-19.51MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-8.89MUSDvs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00USDUpdated Oct 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-27.57MUSDvs all stocks (USD)
Pre-tax Income
-26.44MUSDFY2025 · Dec 31, 2025Net Income
-26.44MUSDFY2025 · Dec 31, 2025EBIT
-27.57MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-27.57MUSDFY2025 · Dec 31, 2025Research & Development
18.15MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
9.42MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.13MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-26.44MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
2.43MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-15.28MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
31.63MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-26.44MUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.03MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.78MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.35MUSDFY2025 · Dec 31, 2025Other Financing Charges
-2.10MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
29.11MUSDFY2025 · Dec 31, 2025Shares Outstanding
26.69MSharesUpdated Oct 28, 2026Float Shares
21.20MSharesUpdated Oct 28, 2026Shares Short
2.52MSharesUpdated Oct 28, 2026Short Ratio
12.29daysvs all stocks
Short % of Shares Outstanding
11.62%vs all stocks
% Held by Insiders
34.43%vs all stocks
% Held by Institutions
33.63%vs all stocks
Total Cash (MRQ)
22.16MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.6800USDUpdated Oct 28, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
1.68xvs Biotechnology peers
Book Value per Share (MRQ)
0.3400USDUpdated Oct 28, 2026Total Assets
31.71MUSDvs all stocks (USD)
Total Current Assets
31.71MUSDFY2025 · Dec 31, 2025Total Liabilities
13.30MUSDFY2025 · Dec 31, 2025Total Non-current Assets
0.00USDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
13.30MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
31.63MUSDFY2025 · Dec 31, 2025Accounts Payable
6.27MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-99.69MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
18.41MUSDvs all stocks (USD)
52-Week Low
5.55USDUpdated Oct 28, 202652-Week High
29.27USDUpdated Oct 28, 202652-Week Change
172.38%vs all stocks
Beta
-0.2420xvs all stocks
50-Day MA
21.70USDUpdated Oct 28, 2026200-Day MA
14.41USDUpdated Oct 28, 2026Avg 10-Day Volume
180.28KSharesUpdated Oct 28, 2026Avg 30-Day Volume
201.05KSharesUpdated Oct 28, 2026Diluted EPS (TTM)
-1.21USDUpdated Oct 28, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -214.6%, lower than 95% of its Biotechnology peers (median -23.8%)Significant
Return on equity: -2.15Industry median: -0.24Industry P5: -1.57Peers compared: 255
Price-to-book is 54.38×, higher than 95% of its Biotechnology peers (median 2.56×)Significant
Price-to-book: 54.38Industry median: 2.56Industry P95: 15.40Peers compared: 255
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 255
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.59
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 36,021,613.518
Companies that share the same coordination system — how they create, deliver, or capture value.
ProKidney Corp
Tier 1ProductionApproval-Gated PipelineRule
Zhongzhu Healthcare Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Hansen Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Candel Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jinhe Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
4D Molecular Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
ChemPartner Pharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nanjing Vishee Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jianmin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule